A Phase 3 study to evaluate weight gain of investigational medication compared to olanzapine in adults with schizophrenia

  • sponsor
    Alkermes Inc.
Updated on 23 November 2020


A Phase 3 study to evaluate weight gain of investigational medication compared to olanzapine in adults with schizophrenia


This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.

All study-related exams, tests, procedures and medication will be provided free of charge. Reasonable compensation for time and travel may be provided.

Clinical Study IdentifierTX145489
SponsorAlkermes Inc.
Last Modified on23 November 2020


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 55 yrs?
Gender: Male or Female
Subject has a body mass index (BMI) of 18.0-30.0 kg/m2, inclusive, at Visit 1 and Visit 2
Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia
Subject is appropriate for outpatient treatment; has no hospitalizations for acute exacerbations of schizophrenia within 6 months before Visit 1
Subject has maintained a stable body weight (change ≤ 5%) for at least 3 months prior to Visit 1 based on self-report
Additional criteria may apply

Exclusion Criteria

Subject has any of the following psychiatric conditions per DSM-5 criteria
Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current, untreated or unstable major depressive disorder
Clinically significant cognitive difficulties present within the past 2 years that could interfere with participation in the study
Drug-induced or toxic psychosis
Any other psychiatric condition that could interfere with participation in the study
Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the investigator
Subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder
Additional criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note